# Dasatinib in Treating Patients With Metastatic Pancreatic Cancer

> **NCT00474812** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 51 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** dasatinib
- **PROCEDURE:** laboratory biomarker analysis
- **PROCEDURE:** physiologic testing

## Key facts

- **NCT ID:** NCT00474812
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2013-01
- **Final completion:** 2014-02
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2015-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00474812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00474812, "Dasatinib in Treating Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00474812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*